Cancer Immunotherapeutics In the News

Nadia Carlesso, M.D. - Profile Photo

Inspiration came early to Nadia Carlesso, M.D., Ph.D., associate director of basic research in the Gehr Family Center for Leukemia Research at City of Hope.


Radiotherapy for Breast Cancer at City of Hope

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.


News Image

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.

Warner-Susanne

At City of Hope since 2015, Susanne Warner, M.D., regularly draws notice and praise for her surgical skills, her research chops and especially her Texas-sized optimism.


Tyler Routh | City of Hope

Tyler Routh is one of 13 leukemia patients who had a remarkable recovery after participating in Dr. Samer Khaled’s CAR T trial.


li-daneng-300x300

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


Ammar Chaudhry

The dynamic young founder and director of City of Hope’s Precision Imaging Lab, Ammar Chaudhry, M.D., is one of the first recipients of the new ORIEN NOVA Award. The $1 million grant will fund research for his breakthrough approach to cancer imaging and diagnosis.


News Image

Study results will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

News Image

City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.

test tubes

City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.


AML | City of Hope

City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.


Blood Cancer | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.


li-daneng-300x300

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.


News Image

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.

Christiane Querfeld, M.D., Ph.D.

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.


Michael Caligiuri

City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.


News Image

City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research (AACR) annual meeting from March 29 through April 3 in Atlanta.

News Image

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma (CTCL).

David Thompson

Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.


Pancreatic Cancer Cell

Longtime "Jeopardy" host Alex Trebek was diagnosed with Stage 4 pancreatic cancer. Susanne Gray Warner, M.D., a surgical oncologist at City of Hope, tells us what you need to know regarding the disease, which is the third-leading cause of cancer death.


News Image

Stephen J. Forman, M.D., the renowned leader of the Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, will receive the 2019 DKMS Mechtild Harf Science Award in honor of his outstanding achievements in cancer immunology, hematology, stem cell transplantation and CAR T cell therapy.

Rare Disease Day | City of Hope

City of Hope has long been renowned for its expertise in treating cancer and diabetes. But specialists here also are tackling lesser-known but equally devastating diseases that may or may not have an oncologic component.


Larry Kwak

City of Hope has earned its third Lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute, which provides $12.5 million for research.


News Image

An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), one of four current NCI-supported lymphoma SPOREs. The grant covers a five-year period and totals $12.5 million.